Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Pfizer has completed the acquisition of two commercially marketed vaccines and portion of related production facilities from Baxter International for $635m.
Subscribe to our email newsletter
Under the deal, Pfizer acquired a portion of Baxter’s facility in Orth, Austria, which manufactures meningitis vaccine, NeisVac-C as well as the encephalitis vaccine, FSME-IMMUN/TicoVac.
NeisVac-C is a vaccine which helps protect against meningitis caused by group C meningococcal meningitis (MenC), while FSME-IMMUN helps protect against tick-borne encephalitis (TBE), an infection of the brain transmitted by the bite of ticks infected with the TBE-virus.
Pfizer Vaccines president and general manager Susan Silbermann said: "NeisVac-C and FSME-IMMUN/Ticovac are a strong fit with our vaccines business and this acquisition adds value, scale and depth to our existing portfolio of innovative vaccines.
"These best-in-class products enable us to reach a broader population with vaccines that prevent infections from serious and often fatal diseases."
Kirkland & Ellis is the legal advisor and Credit Suisse Securities (USA) served as the financial advisor for Pfizer in the transaction.
Image: Pfizer world headquarters. Photo: courtesy of Jim.henderson.